As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
8 Analysts have issued a Virios Therapeutics Inc forecast:
8 Analysts have issued a Virios Therapeutics Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -32 -32 |
390%
390%
|
|
| Net Profit | -40 -40 |
531%
531%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.
| Head office | United States |
| CEO | Gregory Duncan |
| Founded | 2012 |
| Website | dwtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


